Ken Griffin Ikena Oncology, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ikena Oncology, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 165,015 shares of IKNA stock, worth $285,475. This represents 0.0% of its overall portfolio holdings.
Number of Shares
165,015
Previous 244,690
32.56%
Holding current value
$285,475
Previous $403,000
29.28%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding IKNA
# of Institutions
61Shares Held
30.6MCall Options Held
0Put Options Held
0-
Atlas Venture Life Science Advisors, LLC5.02MShares$8.68 Million1.07% of portfolio
-
Bvf Inc San Francisco, CA4.77MShares$8.25 Million0.26% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.09MShares$7.08 Million2.33% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.54MShares$6.12 Million0.14% of portfolio
-
Omega Fund Management, LLC Boston, MA2.25MShares$3.89 Million5.77% of portfolio
About Ikena Oncology, Inc.
- Ticker IKNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,257,500
- Market Cap $62.7M
- Description
- Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...